BODI Bodisen

RNS Number:1183P
Bodisen Biotech Inc
08 January 2007



                 Bodisen Biotech Provides 2006 Updated Guidance
                             and Operations Update

--Company Provides Update on Xinjiang Factory, Signs $43.8 Million in Contracts
                          from November Trade Shows--



Shaanxi, China - January 8, 2007 -- Bodisen Biotech, Inc. (AMEX:BBC, London AIM:
BODI, website: www.bodisen.com), today provided updated guidance for the year
ended December 31, 2006 and an update on its operations.


Update on 2006 Guidance and Operations


The Company stated that it expects to record total annual revenues of
approximately $43 million and net income of approximately $12.9 million or
approximately 30% net income margin, for the twelve months ended December 31,
2006, excluding any extraordinary legal and other expenses related to the
Company's Amex deficiency issue and stockholder lawsuits.  In 2005, the Company
recorded $31.0 million in revenues and net income of $7.4 million.


Factors influencing its results for 2006 include:

*  A delay in the launch of its Mancozeb product line.  Prior to the
   launch, the Chinese government pesticide office instituted a review of all
   pesticide production companies and as a result, required that the Company
   suspend the installation of Mancozeb facility pending the completion of the
   government review.  The Company expects to continue the installation and 
   launch of Mancozeb facility after it receives government pesticide office 
   approval.

*  Road construction in front of one of its factories, which impacted the 
   Company's ability to receive supplies and ship products.  The Company had
   previously stated that it did not expect the road construction to have any
   material impact on its operations but has since determined that the
   construction, which began in mid-2006, did materially impact its business for
   the year. The Company stated that the main road construction is completed and
   that construction on a service road between the main road and the road in 
   front of factory is still underway and is currently expected to be completed 
   by the end of March 2007.

*  A planned month-long shutdown of its factories and existing production lines 
   during the fourth quarter to conduct scheduled maintenance.  The maintenance 
   was conducted to ensure that the Company's lines were in optimum condition to 
   meet 2007 production requirements.


Update on Xinjiang Factory and Clarification of A La Er Agreement


The Company also provided clarification on an agreement it signed in June 2006
with the city government of A La Er, which is located in Xinjiang province.
The Company previously stated that it had signed new product supply contracts
totaling 200,000 metric tons of bio compound fertilizers with A La Er.
Bodisen's agreement with A La Er does not provide any guarantee of product sales
and is not a sales contract.  Under the terms of the agreement the city
government of A La Er has agreed to provide Bodisen with reduced utility rates,
income tax exemption status for all products sold in the region through 2010 and
a portion of test land to demonstrate the effectiveness of its products on local
crop yields.  In exchange, Bodisen agreed to invest in the construction of a
manufacturing facility that will be able to produce up to 200,000 metric tons of
fertilizer and pesticide products.  Construction of the facility began late in
the third quarter of 2006 and the Company currently expects to begin initial
production at the new facility during the third quarter of 2007.  The Company
believes that with the strong government support it is receiving and the
regional market demand for fertilizer and pesticide products that Xinjiang
represents a significant long-term growth opportunity for Bodisen.


Update on November 2006 Trade Show Sales


The Company has signed a total of approximately $43.8 million in contracts for
2007 product delivery with new and existing wholesale distributors during two
major agricultural trade shows in November. The Company stated that its existing
Yanling factory is sufficient to meet these contract demands.


"Generally speaking, we are pleased with the results of the November Yangling
High tech Exhibition and Xiamen Plant Protection Exhibition, which do not
include the partial sales revenues we expect to achieve from our expansion into
the Xinjiang region in 2007," said President Bo Chen.

About Bodisen Biotech, Inc.

Bodisen Biotech Inc. is a leading manufacturer of liquid and organic compound
fertilizers, pesticides, insecticides and agricultural raw materials certified
by the Petroleum Chemical Industry Administrative office of China (Chemical
Petroleum Production Administrative Bureau), Shaanxi provincial government and
Chinese government. Ranked the 16th fastest growing company in China by Forbes
China in January 2006, the Company is headquartered in Shaanxi province and is a
Delaware corporation. The Company's environmentally friendly "green" products
have been proven to improve soil and plant quality, and increase crop yields.

Safe Harbor Statement

This press release may contain forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act of
1995. These statements are based on the current expectations or beliefs of
Bodisen Biotech, Inc. management and are subject to a number of factors and
uncertainties, and the outcome of events may differ materially from those
described in the forward-looking statements, including but not limited to
statements regarding 2006 revenues and net income, the launch of the Mancozeb
production line, and the anticipated completion of road construction.
Investor Relations:
info@bodisen.com


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

TSTBGGDBBXGGGRI

Grafico Azioni Bodisen Biotech (LSE:BODI)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni Bodisen Biotech (LSE:BODI)
Storico
Da Giu 2023 a Giu 2024